Perrigo Company has launched an AB-rated generic version of Androgel Topical Gel, 1.62 percent (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g packet, and 20.25mg/1.25g actuation pump). At generic market formation, an unrelated third party has launched an authorized generic version.
Androgel Topical Gel, 1.62 percent is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel Topical Gel, 1.62 percent for the 12 months ending August 2018 were approximately $1 billion as measured by IQVIA.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, “This launch exemplifies Perrigo’s ongoing commitment to developing quality, high value alternatives in important treatment categories. The Rx team continues to leverage our extended topicals strategy and development capabilities to deliver important products to patients.”
(Source: Perrigo Company plc)
Filed Under: Drug Discovery and Development